View Author
scopus: 7003894388

Haufroid, V.

(Vincent Haufroid)


simvastatin cyp 3a study patient therapy statin allele intron level response cholesterol effect reduction simvastatin therapy genotype model ldlc levels result association t-variant carrier analysis t-variant allele carriers cyp 3a snp cyp 3a activity measurement polymorphism pharmacogenetic lipid rotterdam 180 days allelic table interindividual variability ldl cholesterol t-variant allele observation william status homozygote cyp 3a expression cyp 3a allele reference difference variant rotterdam study statin therapy change lippincott activity interindividual wilkin pharmacogenomic population article variability implication treatment disease participant cohort simvastatin levels van schaik rh genomic reproduction pharmacokinetic nucleotide polymorphism cancer expression cyp 3a polymorphisms cyp 3a genotypes prescription simvastatin efficacy elens population-based cohort study linkage disequilibrium cyp 3a genotype cyp 3a polymorphism interindividual differences copyright sample size




2 Most Recent Publications

CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin (Article)
Elens, L. Nieuweboer, A.J.M. Clarke, S.J. Charles, K.A. Graan, A-J.M. de Haufroid, V. Mathijssen, R.H.J. Schaik, R.H.N. van
2013-01-01
Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study (Article)
Elens, L. Becker, M.L. Haufroid, V. Hofman, A. Visser, L.E. Uitterlinden, A.G. Stricker, B.H.Ch. Schaik, R.H.N. van
2011-12-01